

13. Chappell MC, Schaich CL, Busse LW, Martin GS, Sevransky JE, Hinson JK, et al. Stronger association of intact angiotensinogen with mortality than lactate or renin in critical illness: post-hoc analysis from the VICTAS trial. *Crit Care*. 2024;28(1):333.
14. Eleuteri D, Montini L, Cutuli SL, Rossi C, Alcaro F, Antonelli M. Renin-angiotensin system dysregulation in critically ill patients with acute respiratory distress syndrome due to COVID-19: a preliminary report. *Crit Care*. 2021;25(1):91.
15. Heinicke U, Adam E, Sonntagbauer M, von Knethen A, Zacharowski K, Neb H. Angiotensin II treatment in COVID-19 patients: more risk than benefit? A single-center experience. *Crit Care*. 2020;24(1):409.
16. Busse LW, Wang XS, Chalikhonda DM, Finkel KW, Khanna AK, Szerlip HM, et al. Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. *Crit Care Med*. 2017;45(8):1285-94.
17. Martin C, Medam S, Antonini F, Alingrin J, Haddam M, Hammad E, et al. NOREPINEPHRINE: NOT TOO MUCH, TOO LONG. *Shock*. 2015;44(4):305-9.
18. Legrand M, Khanna AK, Ostermann M, Kotani Y, Ferrer R, Girardis M, et al. The renin-angiotensin-aldosterone-system in sepsis and its clinical modulation with exogenous angiotensin II. *Crit Care*. 2024;28(1):389.
19. Ostermann M, Boldt DW, Harper MD, Lim GW, Gunnerson K. Angiotensin in ECMO patients with refractory shock. *Crit Care*. 2018;22(1):288.
20. Levy B, Lescroart M, Combes A. Use of vasopressors and inotropes in ECMO. *Intensive Care Med*. 2024;50(3):463-6.
21. Busse LW, Barker N, Petersen C. Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options. *Crit Care*. 2020;24(1):36.
22. Bansal M, Mehta A, Wieruszewski PM, Belford PM, Zhao DX, Khanna AK, et al. Efficacy and safety of angiotensin II in cardiogenic shock: A systematic review. *Am J Emerg Med*. 2023;66:124-8.
23. Cutler NS, Rasmussen BM, Bredeck JF, Lata AL, Khanna AK. Angiotensin II for Critically Ill Patients With Shock After Heart Transplant. *J Cardiothorac Vasc Anesth*. 2021;35(9):2756-62.
24. Wieruszewski PM, Radosevich MA, Kashani KB, Daly RC, Wittwer ED. Synthetic Human Angiotensin II for Postcardiopulmonary Bypass Vasoplegic Shock. *J Cardiothorac Vasc Anesth*. 2019;33(11):3080-4.
25. Jackson T, Corke C, Agar J. Enalapril overdose treated with angiotensin infusion. *Lancet*. 1993;341(8846):703.
26. Newby DE, Lee MR, Gray AJ, Boon NA. Enalapril overdose and the corrective effect of intravenous angiotensin II. *Br J Clin Pharmacol*. 1995;40(1):103-4.
27. Trilli LE, Johnson KA. Lisinopril overdose and management with intravenous angiotensin II. *Ann Pharmacother*. 1994;28(10):1165-8.
28. Chen A, Wong A. The Role of Angiotensin II in Poisoning-Induced Shock-a Review. *J Med Toxicol*. 2022;18(2):145-54.
29. Lambden S, Creagh-Brown BC, Hunt J, Summers C, Forni LG. Definitions and pathophysiology of vasoplegic shock. *Crit Care*. 2018;22(1):174.
30. Ratnani I, Ochani RK, Shaikh A, Jatoi HN. Vasoplegia: A Review. *Methodist Debakey Cardiovasc J*. 2023;19(4):38-47.
31. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med*. 2008;358(9):877-87.
32. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. *Jama*. 2016;316(5):509-18.
33. Balik M, Novotny A, Suk D, Matousek V, Maly M, Brozek T, et al. Vasopressin in Patients with Septic Shock and Dynamic Left Ventricular Outflow Tract Obstruction. *Cardiovasc Drugs Ther*. 2020;34(5):685-8.
34. Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. *Crit Care*. 2014;18(5):534.
35. Zangrillo A, Landoni G, Beretta L, Morselli F, Serpa Neto A, Bellomo R. Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series. *Crit Care*. 2020;24(1):227.
36. Agency EM. EU Panel Backs Angiotensin II (Giapreza) for Septic Shock 28. 6. 2019
37. Caragata R, Johnston SA, Chan JW, Starkey G, Bellomo R. Angiotensin-II and Thromboembolic Events: A Systematic Review. *Crit Care Med*. 2024;52(12):1894-905.
38. Legrand M, Zarbock A. Ten tips to optimize vasopressors use in the critically ill patient with hypotension. *Intensive Care Med*. 2022;48(6):736-9.